Colonization with B. fragilis protects mice against development of colon cancer. Colonization with B. fragilis protects mice against development of colon.

Slides:

Advertisements

Similar presentations

Prostaglandin E2 (PGE2) induces no significant alteration in circadian locomotor activity. Prostaglandin E2 (PGE2) induces no significant alteration in.

Advertisements

Supplementary Figure S13

A 43kD protein from the herb, Cajanus indicus L

Effects of senescent cells on activity.

Volume 32, Issue 3, Pages (March 2010)

Binding of 53BP1 on uncapped telomeres.

Volume 25, Issue 4, Pages (April 2014)

Volume 15, Issue 2, Pages (February 2009)

Volume 23, Issue 1, Pages (January 2013)

Course of P. chabaudi AS infection and pregnancy outcome in ad libitum orally delivered TPL treatment from ED2 to ED12. Course of P. chabaudi AS infection.

Localization of Gammaproteobacteria and evidence of Proteobacteria migration into the crypts within the distal colon of mice inoculated with C. rodentium.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Volume 141, Issue 4, Pages e2 (October 2011)

Treatment of SFTSV-infected IFNAR−/− mice with T-705 or ribavirin.

BV6 increases tumor burden in bone.

Volume 40, Issue 1, Pages (January 2014)

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Volume 32, Issue 3, Pages (March 2010)

Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis. Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis.

Histological changes in mouse colons after DSS treatment.

Histologic characterization of ACF, and the effects of tocopherol treatment on ACF formation, 4-HNE levels, and nitrotyrosine levels in the colon. Histologic.

Volume 19, Issue 11, Pages (June 2017)

Valproic acid (VPA) prevents small cell lung carcinoma (SCLC) tumour growth in combination with cyclophosphamide, vindesine and doxorubicin. Valproic acid.

Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer. Sildenafil suppresses polyp formation in the AOM/DSS model of colon cancer.

Effects of tumour size on response to treatment in the KPC model.

A: Chemical structure of pterosin A

MRP2 inhibition mitigates pulmonary burden and bacteremia following lung challenge with S. pneumoniae. MRP2 inhibition mitigates pulmonary burden and bacteremia.

Figure 1 EAE severity and CNS pathology in Dex-treated MIF−/− and Wt mice Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Sildenafil protects the intestinal epithelium from DSS-induced damage.

Prime and boosts with PBK001 vaccine provided 100% protection with low bacterial burden in organs. Prime and boosts with PBK001 vaccine provided 100% protection.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Intranasal immunization of mice with S

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Inhibiting or altering the timing of microbial antigen encounter results in inflammatory T cell responses against gut bacteria and worsened colitis upon.

Effects of AG on the colon histology score in the acute DSS colitis model. Effects of AG on the colon histology score in the acute DSS colitis model. Ten.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Quercetin induces arrest in G1 phase of cell cycle in P39 xenografts.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

LEfSe comparison analysis between the control and ciprofloxacin or vancomycin-imipenem groups at the end of antibiotic treatment (A or B, respectively)

Inflammation-induced tumorigenesis is commensal dependent.

5FU-induced specific activation of CD8+ T cells.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Neutralization of CSF1 and Ad5-HRG treatment.

BTK-activated signaling regulates PDAC tumorigenesis.

Influenza vaccine enhances NK cell function through IFN-α.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

B. fragilis utilizes TLR2 signaling for its protective role against the development of colitis-associated cancer in mice. B. fragilis utilizes TLR2 signaling.

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

PDL192 and inhibit the growth of xenograft tumors.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

GCS-100 selectively kills KRAS-addicted lung tumors.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

BV6 increases bone metastasis.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Tumor growth in female progeny with prenatal/maternal, postnatal early-life, and postnatal adult BSp dietary administrations. Tumor growth in female progeny.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

Colonization with B. fragilis protects mice against development of colon cancer. Colonization with B. fragilis protects mice against development of colon cancer. (A) Schematic overview of the azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colorectal cancer model. C57BL/6J (B6) mice were treated orally with PBS (control), B. fragilis, or B. fragilis ΔPSA three times a week starting a week prior to AOM injection until the end of the experiment (8 mice per group). After an initial AOM intraperitoneal injection (10 mg/kg), 3% DSS was administered via the drinking water for 6 days followed by administration of regular drinking water. The mice underwent a second DSS treatment cycle with 3% DSS-treated water on day 25 for 6 days and a third cycle with 1.5% DSS-treated water on day 55 for 4 to 6 days. The mice were sacrificed on day 81 post-AOM injection. (B) Percent weight change in the indicated groups during DSS treatment. (C) Number of tumors in the distal colon (left) and the sum of tumor size (right) in the indicated groups on day 81 of AOM-DSS treatment. (D) Scores of hyperplasia (left) and dysplasia (right) from longitudinal sections of distal colon of the indicated groups on day 81 of AOM-DSS treatment. Data are representative of results from at least two experiments. Statistical significance was calculated using unpaired Student's t tests and nonparametric Mann-Whitney tests. *, P < 0.05 (in all panels). Yun Kyung Lee et al. mSphere 2018; doi:10.1128/mSphere.00587-18